ist noch jemand in amarin (amrn) investiert?
Seite 1 von 3 Neuester Beitrag: 23.02.05 11:07 | ||||
| Eröffnet am: | 18.07.03 19:41 | von: Ramses II | Anzahl Beiträge: | 61 |
| Neuester Beitrag: | 23.02.05 11:07 | von: xxxlO.st.arr. | Leser gesamt: | 3.964 |
| Forum: | Börse | Leser heute: | 2 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 > | ||||
grüße
Bin nicht ganz sicher, wie das Erste Quartal konkret sein wird. Aber ich bin sicher, daß es nicht schlecht sein wird! NAchdem ja jetzt die Umschuldung/Entschuldung erfolgt ist, hat Amarin keine oder fast keine Zinsaufwendungen zu tragen. Alleine dies müßte schon stark positiv in der Bilanz wirken.
Elan geht es auch besser, und da Elan die Mutter ist, und 28 Prozent hält sie zudem an Amarin, ist dies sicher beruhigend!
Belastend war sicher der Rücktritt von einigen Vorständen!
Aber es gab keinen (!) Bilanzskandal! Alle Bilanzen sind sauber! Und die Firma erscheint mir sehr vernünftig positioniert, auch wenn das US-Geschäft jetzt nicht mehr so ganz tolle Margen bringen wird in Zukunft! Du weißt ja, da hat es auch einen Teilrückzug gegeben. Andererseits hat Amarin ja dennoch sprudelnde Gewinne in Aussicht, sobald das neue Medikament zugelassen wird, weil es im Vertrag so steht, daß Amarin, obwohl Rechte verkauft, dennoch mitpartizipieren darf am Erfolg, soll heißen bis zu 8 Millionen USD bekommt! Cash!
Und das zweite Medikament ist auch schon in Phase III! Und dann gibt es noch die etlichen Distributionsrechte und Cooperationsverträge, z.B. mit Roche, für US-Vertrieb!
Cash ist auch ordentlcih in der Kasse, soweit ich weiß fast 18 Millionen USD!
Fazit: Ich habe Limit drinnen und hoffe, die Stücke zu bekommen! 3,500 Stück möchte ich dazukaufen!
Abschlußfrage:
Glaubst Du an unter 1 USD im Kurs?
LG
Ostarrichi
Habe gerade mit USD 1,06 2,000 Stk bekommen! Tss, ich finde das bedenklich, daß es so viele Unbedachte Menschen gibt!
Sollte es unter 1 USD fallen, dann kaufe ich volles Rohr, bei 90 US-Cent ca. 10,000 Stk! Außer es gibt eine Bad-News! Aber das bezweifle ich stark!
LG
Ostarrichi
Habe schon 3 teilsausführungen und erst die Hälfte miner Order ist durch!
Hier mal die Liste der Aktionäre!
TOP INSTITUTIONAL HOLDERS
Holder Shares % Out Value* Reported
Pequot Capital Management, Inc. 677,800 8.8 $1,043,811 31-Dec-03
Citigroup Inc. 1,155,540 15 $1,779,531 31-Dec-03
MWN Ltd. 30,026 0.39 $46,240 31-Dec-03
United States Trust Company of New York 10,000 0.13 $15,399 31-Dec-03
RBC Dain Rauscher 2,500 0.03 $3,849 31-Dec-03
TOP MUTUAL FUND HOLDERS
Holder Shares % Out Value* Reported
Smith Barney Fundamental Value Fund Inc 1,155,540 15 $3,119,958 30-Sep-03
Marketocracy Masters 100 Fund 15,993 0.21 $24,629 31-Dec-03
Weißt Du übrigens, wann der nächste Quartalsbericht ist?
Iran Garland hat mir noch nicht geantwortet. Amarin müßte ein gutes 1 Quartal gehabt haben, zumindest der Finanz-Cash Flow war sicher enorm positiv. Operativ wirds aber leider noch dauern! Umsatz ist wohl sehr schwach! Allerdings keine Zinsbelastungen mehr durch Kredite, ist alles zurückgezahlt. Elan hat 63 Millionen USD gezahlt, indirekt und direkt, an Amarin! Weiß nicht, warum der Kurs so schwächelt! Mir vergeht schon wieder der Appetit auf die Jause! :((
LG
Ostarrichi
Jetzt hängt alles von Lax 101 und Permax ab! Alles dauert halt, leider! Was machen wir?
Ließ bitte hier:
LONDON, May 12 /PRNewswire-FirstCall/ -- Amarin Corporation plc today reported its results for the quarter ended March 31, 2004.
Revenues for the first quarter of 2004, which relate entirely to discontinued operations, were $1.0 million compared to $3.3 million for the same quarter in 2003, also entirely from discontinued operations. The first quarter 2003 revenues are after exceptional charges of $6.1 million relating to Permax inventories and deductions.
During the first quarter of 2004 and as previously reported, Amarin sold the majority of its US operations to Valeant Pharmaceuticals International. This sale, which resulted in a loss in the quarter of $2.4 million, comprised Amarin''s:
-- US commercial operations and subsidiary, Amarin Pharmaceuticals Inc; -- rights to Permax and the Primary Care Portfolio of marketed products; and -- rights to the development compound, Zelapar.
Amarin remains responsible for undertaking further safety studies on Zelapar and is liable for up to $2.5 million of development costs. It is anticipated that these cost will be incurred in the second quarter and will contribute to a second quarter loss. Under the terms of the sale to Valeant, Amarin will be paid contingent milestones totalling $8 million if these studies show satisfactory results and Zelapar is approved by the US Food and Drug Administration. Neither of these milestones had been earned in the first quarter and will be recognized as income when and if the contingent events have been satisfied.
Rick Stewart, Chief Executive Officer of Amarin commented, "the restructuring plans were accomplished successfully in the first quarter of 2004 with the sale of Amarin Pharmaceuticals Inc. The improvement in Amarin''s balance sheet will now allow the Company greater flexibility to implement its future growth plans. In the short term we will concentrate on progressing LAX- 101 for Huntington''s disease into additional Phase III clinical trials, further balance sheet improvements and building a late-stage neuroscience development pipeline via in-licensing and acquisitions."
There has been no resolution to the closing balance sheet and in-market inventory contingencies disclosed in our 2003 Annual Report filed with the Securities and Exchange Commission under Form 20-F.
Also during the first quarter 2004 and again as previously reported, Amarin settled its debt obligations with Elan through a cash payment of $17.2 million (part of which represented the cost of acquiring Zelapar that was concurrently sold to Valeant), issuing a new $5 million 5-year loan note and issuing 500,000 warrants over ordinary shares. Details of Elan debt settlement are explained more fully in our 2003 Annual Report. The settlement with Elan resulted in a gain of $25.6 million. A deferred tax charge of $7.5 million arises on this gain, giving an after tax impact of $18.1 million or $1.01 per American Depositary Share (ADS).
For the first quarter of 2004, the net income was $13.8 million or $0.77 per fully diluted ADS, versus a net loss of $3.7 million or $0.26 per ADS for the first quarter ended March 31, 2003. The 2003 first quarter net loss reflected charges totalling $7.3 million relating to Permax inventory and deductions and a credit of $7.5 million relating to a waiver of part of the Elan debt.
The results for the first quarter 2004 and the corresponding quarter in 2003 comprise a combination of continuing expenses, discontinued revenues and expenses and the exceptional items outlined above. The operating loss from continuing business for the first quarter 2004 was $1.6 million (compared to $1.9 million for the same quarter 2003) and reflects the head office operating expenses and LAX-101 product rights amortization. Ongoing operating costs for the head office are approximately $1.5 million per quarter.
At March 31, 2004 Amarin had cash of $11.2 million and based on the current head office burn rate, Zelapar development costs and working capital movements, is anticipated to be sufficient into the third quarter 2005.
Rick Stewart continued, "plans for enhancing shareholder value by progressing LAX-101 into additional Phase III clinical trials and building the neuroscience development pipeline are progressing according to schedule. We will update shareholders when appropriate. A meeting was held with the Food and Drug Administration during the quarter regarding the clinical trial protocol for additional LAX-101 Phase III studies. As a result of that meeting revisions have been made to the protocol and we are optimistic that the studies could start in the third quarter of 2004."
Amarin is also today announcing that its Chief Financial Officer, Ian Garland is to leave the company to join another UK based pharmaceutical company. The Chief Financial Officer role is to be filled by Alan Cooke. Previously, Mr. Cooke was Vice President, Global Strategic Planning at Elan Corporation, plc. Mr. Cooke is a chartered accountant and spent four years with KPMG, Dublin. Mr. Cooke will be invited to join the board of Amarin Corporation.
Rick Stewart continued, "we would like to thank Ian Garland for his successful contribution to the restructuring process and wish him well with his future endeavours. We welcome Alan Cooke to the board of Amarin."
Amarin also announces that it will apply for a NASDAQ SmallCap market listing.
Amarin Corporation plc is a specialty pharmaceutical company focused in neuroscience. The Company plans to become a leader in these therapeutic categories by providing innovative products and solutions that address significant unmet medical needs. Amarin has a late-stage development candidate, LAX-101, a proprietary compound for Huntington''s disease.
For press release and other Company information, visit our web site at http://www.amarincorp.com/ .
Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company''s actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialisation, the impact of competitive products and patents, the ability of the Company to continue to fund its operations and product development as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation''s Annual Report for 2003 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The Company assumes no obligation to update information on its expectations.
Amarin Corporation plc Period Ended 31 March 2004 Selected Data (UK GAAP - UNAUDITED) Three months ended 31 March 2004 Pre Exceptional Exceptional Total Total $''000 $''000 $''000 $''000 Revenue: Licensing & development fees - - - - Product sales & royalties - - - - Total revenue from continuing activities - - - - Revenues from discontinued activities 1,046 - 1,046 3,267 Total revenues 1,046 - 1,046 3,267 Cost of sales: Direct costs 107 - 107 5,400 Cost of sales from discontinued activities 107 - 107 5,400 Gross profit/(loss) Continuing activities - - - - Discontinued activities 939 - 939 (2,133) Total gross profit/(loss) 939 - 939 (2,133) Operating expenses/(income): Selling, General & Administrative 1,466 - 1,466 1,741 Amortisation of intangible assets 144 - 144 125 Operating expenses from continuing activities 1,610 - 1,610 1,866 Selling, General & Administrative 1,575 - 1,575 4,125 Amortisation of intangible assets - - - 1,223 Gain on renegotiation of Elan debt - (25,586) (25,586) (7,500) Selling, General & Administrative from discontinued activities 1,575 (25,586) (24,011) (2,152) Research & development from discontinued activities - - - 1,488 Operating expenses/(income) from discontinuing activities 1,575 (25,586) (24,011) (664) Total selling, general & administrative 3,185 (25,586) (22,401) (286) Total research & development - - - 1,488 Total operating expenses/(income) 3,185 (25,586) (22,401) 1,202 Operating (loss) from continuing activities (1,610) - (1,610) (1,866) Operating (loss)/profit on discontinued activities (636) 25,586 24,950 (1,469) Total operating (loss)/profit (2,246) 25,586 23,340 (3,335) Exceptional income/(expense) - discountinued activities Escrow proceeds of Q4 2003 Swedish disposal 350 - Loss on disposal of US operations and certain products (2,376) - (Loss)/profit on ordinary activities before interest Continuing activities (1,610) (1,866) Discontinued activities 22,924 (1,469) 21,314 (3,335) Net interest payable (29) (255) Foreign exchange gain - - Income/(loss) before taxes 21,285 (3,590) Income tax (expense) (7,500) (102) Dividends payable - (24) Net income/(loss) for the period 13,785 (3,716) Weighted average shares - basic 17,940 14,567 Weighted average shares - diluted 17,941 15,175 Income/(loss) per share: Basic 0.77 (0.26) Diluted 0.77 (0.26) Amarin Corporation plc Period Ended 31 March 2004 Selected Data (UK GAAP - UNAUDITED) As at 31 March 2004 2003 $''000 $''000 1. Select Balance Sheet Data Net current assets/(liabilities) 8,260 (1,494) Cash and debtors 12,073 24,051 Total assets 16,254 77,261 Long term creditors and provisions [see note 4] (5,000) (36,908) Called up share capital [ordinary shares] 29,088 29,076 Total shareholders'' funds 7,441 10,166 Three months ended 31 March 2004 2003 2. EBITDA $''000 $''000 Profit/(loss) for period 13,785 (3,716) amortisation 144 1,348 interest 29 255 taxation 7,500 102 dividend - 24 EBITDA 21,458 (1,987) 3. The selected financial data set out above should be read in-conjunction with our 2003 20-F Annual Report which is filed with the SEC. 4. The long term loan can potentially be called for early repayment upon the approval of Zelapar by the FDA. More details of the terms of this loan are given in our 2003 20-F Annual Report and other filing with the SEC. 5. Shareholders'' Equity 31-Mar-04 $''m UK GAAP 7.4 Lax-101 product rights (3.9) Income recognition (0.6) Preference dividends 0.5 US GAAP 3.4
Amarin Corporation plc
© PR Newswire
LG
Ostarrichi
Habe reduziert mit 0,97 vor einigen Tagen! Leider! Jetz halte ich 5,000 Amarin und werde damit wahrscheinlich erst im Winter glücklich sein!
Habe eine Good News zum Trost: Die Altaktionäre waren wehement gegen eine Kapitalerhöhung bei Amarin, und s omit ist nichts verwässert worden beim letzten Schuldennachlaß. Wenn die aber gegen die KE waren, dann ist auch klar, daß es Amarin locker auch so schafft! Da zudem die Nominale der Aktie 1 Pfund ist, also etwa USD 1,60, kann man beruihgt in die Zukunft sehen, wenngleich auch viel Geduld angesagt sein wird.
Bei 50 Cent (hoffentlich kommts nicht soweit) kaufe ich zudem voll zurück! Dann könnte ich mir auch vorstellen, 25,000 Stück zu erwerben!
LG
Ostarrichi
